New research into importance of skin surveillance to save lives from melanoma
4 November 2021
New research has provided evidence that routine skin checks by a health professional, coupled with checking your own skin, are vital in saving lives from melanoma – the most deadly form of skin cancer.
Australia has the highest melanoma rates in the world, with one person dying every 6 hours from the disease. Melanoma is also the most common cancer in 20 to 39-year-olds.
The first sign of melanoma is often a new or changing spot or mole on the skin, and the ABCDE guidelines are a helpful tool to identify a melanoma. However, melanoma can vary greatly in its appearance and many subtle clues can only be detected by a trained healthcare professional using a magnifying tool, known as a dermatoscope, to check the skin.
The research, published today in the prestigious journal JAMA Dermatology, found that in a group of 2,452 patients diagnosed with melanoma, slower-growing melanomas were more likely to be detected at a routine skin check and be thinner, whereas faster-growing melanomas were more likely to be patient-detected and thicker. It was estimated that patients whose melanoma was detected by their doctor during a routine skin check were 32% less likely to die from melanoma compared to patients who identified their own melanoma.
The study also found that melanomas easily detected using the ABCDE rule were more likely to be detected by the patients (70%), whereas atypical ones were more often detected by a doctor during a routine skin check.
“This evidence highlights the importance of not only knowing your own skin and seeking advice from your doctor if you notice any changes but also the critical role of trained healthcare professionals for detecting melanomas early, before they have had a chance to spread,” said study author Prof Richard Scolyer AO, pathologist and Co-Medical Director of Melanoma Institute Australia.
Current Australian guidelines recommend that individuals at very high risk of melanoma receive full skin examinations every 6 months. However, melanoma screening programs for the general population are not currently undertaken in Australia because of inadequate evidence that melanoma screening ultimately saves lives, uncertainty about overdiagnosis and unnecessary biopsy, and limited evidence that it is cost effective.
In the last decade there has been renewed interest in melanoma screening, driven by the changing landscape of melanoma care.
“We found that melanoma detection during a routine skin check was associated with lower risk of dying from any cause, but it was not statistically significant for melanoma-specific mortality,” said cancer epidemiologist and lead author Prof Anne Cust, from Melanoma Institute Australia, The Daffodil Centre and The University of Sydney. “Based on our early findings, the cost-effectiveness of a population melanoma screening program should be re-assessed, and a large randomised controlled trial is needed to provide definitive evidence.”
Melanoma Institute Australia has recently launched its ‘Game On Mole’ awareness campaign which uses slogan t-shirts to start conversations about melanoma early detection, and urges Australians to take photos of their skin and monitor for any changes.
To join the campaign and buy the ‘Game On Mole’ t-shirt, go to www.gameonmole.com.au.
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
We value your privacy and want you to be familiar with how we collect, use and disclose your information.
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.
MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.